Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420539 | 0.88 | SLC22A12 (0.60) | SLC22A12ALDH1A1HTTKMT2AGAA | |
| SCHEMBL2679426 | 0.88 | SLC22A12 (0.45) | SLC22A12TSHRALDH1A1HTTKMT2A | |
| SCHEMBL14700701 | 0.88 | TSHR (0.53) | SLC22A12TSHRALDH1A1HTTGAA | |
| SCHEMBL21004933 | 0.87 | SLC22A12 (0.53) | SLC22A12ALDH1A1HTTGAAALOX15 | |
| SCHEMBL10177200 | 0.86 | ALDH1A1 (0.46) | TSHRALDH1A1KMT2AGAAHSD17B10 | |
| SCHEMBL1299896 | 0.86 | SLC22A12 (0.48) | SLC22A12TSHRALDH1A1KMT2AGAA | |
| SCHEMBL4736052 | 0.85 | SLC22A12 (0.45) | SLC22A12ALDH1A1HTTKMT2AGAA | |
| SCHEMBL10177127 | 0.81 | SLC22A12 (0.43) | SLC22A12ALDH1A1HTTKMT2AKDM4E | |
| SCHEMBL10176730 | 0.80 | SLC22A12 (0.47) | SLC22A12ALDH1A1 | |
| SCHEMBL4735698 | 0.80 | SLC22A12 (0.48) | SLC22A12ALDH1A1KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-8633232-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8357713-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8283369-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES. INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885TSHR 4035/4885ALDH1A1 186/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885TSHR 4035/4885ALDH1A1 186/4885 |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | XDH, PON1, OAT | SLC22A12 1095/4885TSHR 4281/4885ALDH1A1 276/4885 |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885TSHR 4035/4885ALDH1A1 186/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885TSHR 4035/4885ALDH1A1 186/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885TSHR 4035/4885ALDH1A1 186/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885TSHR 4035/4885ALDH1A1 186/4885 |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | XDH, PON1, OAT | SLC22A12 1095/4885TSHR 4281/4885ALDH1A1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.